Top

Published in:

Open Access 01-12-2016 | Mini review

Update on host-pathogen interactions in cystic fibrosis lung disease

Authors: Andreas Hector, Nina Frey, Dominik Hartl

Published in: Molecular and Cellular Pediatrics | Issue 1/2016

Abstract

Bacterial and fungal infections are hallmarks of cystic fibrosis (CF) lung disease. In the era of long-term inhaled antibiotics and increasing CF patient survival, new “emerging” pathogens are detected in CF airways, yet their pathophysiological disease relevance remains largely controversial and incompletely defined. As a response to chronic microbial triggers, innate immune cells, particularly neutrophils, are continuously recruited into CF airways where they combat pathogens but also cause tissue injury through release of oxidants and proteases. The coordinated interplay between host immune cell activation and pathogens is essential for the outcome of CF lung disease. Here, we provide a concise overview and update on host-pathogen interactions in CF lung disease.

Adjemian J, Olivier KN, Prevots DR (2014) Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 190:581–586PubMedCentralCrossRefPubMed

Amin R, Dupuis A, Aaron SD et al (2010) The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137:171–176CrossRefPubMed

Bendiak GN, Ratjen F (2009) The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 30:587–595CrossRefPubMed

Branzk N, Lubojemska A, Hardison SE et al (2014) Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat Immunol 15:1017–1025PubMedCentralCrossRefPubMed

Brinkmann V, Zychlinsky A (2007) Beneficial suicide: why neutrophils die to make NETs. Nature reviews. Microbiology 5:577–582PubMed

Cantin AM, Hartl D, Konstan MW et al (2015) Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 14:419–430CrossRefPubMed

Chmiel JF, Aksamit TR, Chotirmall SH et al (2014) Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 11:1120–1129CrossRefPubMed

Chmiel JF, Aksamit TR, Chotirmall SH et al (2014) Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc 11:1298–1306CrossRefPubMed

Chotirmall SH, Greene CM, Mcelvaney NG (2010) Candida species in cystic fibrosis: a road less travelled. Med Mycol 48:S114–S124CrossRefPubMed

10.

Chotirmall SH, O’donoghue E, Bennett K et al (2010) Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest 138:1186–1195CrossRefPubMed

11.

Courtney JM, Dunbar KE, Mcdowell A et al (2004) Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 3:93–98CrossRefPubMed

12.

De Baets F, Schelstraete P, Van Daele S et al (2007) Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 6:75–78CrossRefPubMed

13.

Goss CH, Mayer-Hamblett N, Aitken ML et al (2004) Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59:955–959PubMedCentralCrossRefPubMed

14.

Goss CH, Muhlebach MS (2011) Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 10:298–306CrossRefPubMed

15.

Hansen CR, Pressler T, Nielsen KG et al (2010) Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 9:51–58CrossRefPubMed

16.

Hartl D, Gaggar A, Bruscia E et al (2012) Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 11:363–382CrossRefPubMed

17.

Hassett DJ, Korfhagen TR, Irvin RT et al (2010) Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 14:117–130CrossRefPubMed

18.

Hector A, Schafer H, Poschel S et al (2015) Regulatory T cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am J Respir Crit Care Med 191(8):914–923CrossRefPubMed

19.

Ingersoll SA, Laval J, Forrest OA et al (2015) Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J Immunol 194:5520–5528CrossRefPubMed

20.

Kruger P, Saffarzadeh M, Weber AN et al (2015) Neutrophils: between host defence, immune modulation, and tissue injury. PLoS Pathog 11, e1004651PubMedCentralCrossRefPubMed

21.

Mall MA, Hartl D (2014) CFTR: cystic fibrosis and beyond. Eur Respir J 44:1042–1054CrossRefPubMed

22.

Nagano Y, Cherie MB, Goldsmith CE, et al. (2009) Emergence of Scedosporium apiospermum in patients with cystic fibrosis. BMJ Case Reports:bcr2007119503

23.

Nick JA (2003) Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med 24:693–702CrossRefPubMed

24.

Regamey N, Tsartsali L, Hilliard TN et al (2011) Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 67(2):164–170CrossRefPubMed

25.

Regan KH, Bhatt J (2014) Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev 10, CD009876PubMed

26.

Shoseyov D, Brownlee KG, Conway SP et al (2006) Aspergillus bronchitis in cystic fibrosis. Chest 130:222–226CrossRefPubMed

27.

Surette MG (2014) The cystic fibrosis lung microbiome. Ann Am Thorac Soc 11(Suppl 1):S61–S65CrossRefPubMed

28.

Tang AC, Turvey SE, Alves MP et al (2014) Current concepts: host-pathogen interactions in cystic fibrosis airways disease. Eur Respir Rev 23:320–332CrossRefPubMed

29.

Teichgraber V, Ulrich M, Endlich N et al (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14:382–391CrossRefPubMed

30.

Waters V, Atenafu EG, Salazar JG et al (2012) Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 11:8–13CrossRefPubMed

31.

Waters V, Ratjen F (2014) Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 12, CD010004PubMed

32.

Waters V, Yau Y, Prasad S et al (2011) Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 183:635–640CrossRefPubMed

33.

Waters VJ, Ratjen FA (2014) Is there a role for antimicrobial stewardship in cystic fibrosis? Ann Am Thorac Soc 11:1116–1119CrossRefPubMed

34.

Waters VJ, Stanojevic S, Sonneveld N et al (2015) Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. J Cyst Fibros 14(6):755–762CrossRefPubMed

35.

Yonker LM, Cigana C, Hurley BP et al (2015) Host-pathogen interplay in the respiratory environment of cystic fibrosis. J Cyst Fibros 14:431–439CrossRefPubMed

Title: Update on host-pathogen interactions in cystic fibrosis lung disease
Authors: Andreas Hector
Nina Frey
Dominik Hartl
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Molecular and Cellular Pediatrics / Issue 1/2016
Electronic ISSN: 2194-7791
DOI: https://doi.org/10.1186/s40348-016-0039-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Update on host-pathogen interactions in cystic fibrosis lung disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

MicroRNA in late lung development and bronchopulmonary dysplasia: the need to demonstrate causality

Alveologenesis: key cellular players and fibroblast growth factor 10 signaling

Leukocyte recruitment in preterm and term infants

Wilms’ tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes

Genetics of irritable bowel syndrome

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever